Boston Immune Technologies and Therapeutics

Company

Boston Immune Technologies and Therapeutics

Biotechnology Research Boston, Massachusetts, United States 5 employees

Employees: 5
Contacts: 3
Emails: 3
Phones: 1

www.bostonimmunetech.com LinkedIn

Boston Immune Technologies and Therapeutics Overview

Headquarters: Boston, Massachusetts, United States
Website: www.bostonimmunetech.com
Industry: Biotechnology Research
Employees: 5
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)

About Boston Immune Technologies and Therapeutics

BITT’s dominant antibody antagonist antibody platform (DOMabTM) is a proprietary discovery platform for the development of antagonist monoclonal antibodies to the TNF superfamily. DOMab antibodies create unique surface stabilization of anti-parallel dimers for altering intracellular signaling. For TNF superfamily proliferative pathways (such as TNFR2, TRAIL and HVEM), antagonism causes cell death. For death receptors (such as CD40, CD27 and OX40), antagonism permits cell growth. Our technology’s ability to create antibodies that target only rapidly proliferating cells opens the door to TNF superfamily targets that were previously considered undruggable or limited by toxicology.

Boston Immune Technologies and Therapeutics Contact Details

People in AeroLeads: 3
With contact data: 3
Email contacts: 3; 100.0% coverage
Phone contacts: 1; 33.3% coverage

Boston Immune Technologies and Therapeutics Org Chart

Sample employees and titles

Name	Title	Location	Contact
David Brooks	Chief Medical Officer, Boston Immune Technology and Therapeutics	Boston, Massachusetts, United States	Email
Mohammad Razvi Md, PMP	Director Clinical Operations/clinical Operations Consulting/fractional	Washington Dc-baltimore Area, United States	Email
Russell Lamontagne		Boston, Massachusetts, United States	Email Phone